Check out this newly released resource on biosimilars!
Biosimilars are changing the game, and it's time to get ahead of the curve! 🚀 Introducing "Biosimilars for Employer Consultants," a resource made to help you understand the benefits of biosimilars and how they're reshaping managed care pharmacy. Consultants, unlock the potential for cost savings, increased access, and improved patient outcomes. 👉 Want to be in the know? Check it out now! ➡️ https://bit.ly/3Fkirtz
Here's to a future where everyone has access to the medicines they need! https://lnkd.in/gFJWGx2T
In 2023, the average out-of-pocket cost for a generic medicine was $7.05, while the average out-of-pocket cost for a brand drug was nearly four times higher — at $27.10, reports the Association for Accessible Medicines' 2024 U.S. Generic & Biosimilar Medicines Savings Report 📕 The low prices delivered by generic competition are critical to ensuring that life-saving medications are more affordable and widely available. But, while price competition is a long-standing feature of the U.S. generic drug market, generic medicines are seeing extended and unchecked price deflation. In fact, according to the report, the overall value of all generic sales in the U.S. has declined by $6.4 billion since 2019 despite increased volume and new generic launches. This poses the risk of rendering the market unsustainable for many manufacturers. Without legislative and regulatory action by policymakers in Congress, the White House and state governments, it is very possible that the drug shortages we’ve seen recently will be further exacerbated, hindering the ability for patients and caregivers to access the medicines they need, when they need them. What happens next must happen now. Learn more about what Sandoz is doing at www.us.sandoz.com #PioneeringAccess
What an experience to hear Bill Nye “Science Guy” live on stage! Thank you Prime Therapeutics for a great program!
“You must participate as a citizen in the health of everyone.” - Bill Nye Bill Nye (the Science Guy) chats with our CIO Dinesh Kandanchatha about developments in artificial intelligence (AI) and its potential impact on the health care industry and beyond.
Exciting to be a part of this journey!
US ONLY: We are expanding our #ophthalmology and off-patent medicine portfolio by entering an agreement to acquire a leading FDA-approved #biosimilar. Learn more: http://bit.ly/3S6OG5k
Excellent read to see how other sectors of pharmacy are working to bring awareness to biosimilars.
Humira biosimilars are here. Is your specialty pharmacy ready?
I am hiring! Interested in pioneering medication access for patients? Consider applying for my team.
What an incredible moment for team Sandoz! So excited to be a part of this journey! #newsandoz
Today, Sandoz is officially an independent company – marking the start of an exciting new era that will allow us to build on our rich heritage of quality and access in a bold new way. Our purpose of #PioneeringAccessforPatients remains clear and unchanged, and I couldn’t be more thrilled to be embarking on this new journey as a standalone organization. Our future is bright, and we are moving forward with renewed energy as we build on our momentum in North America with a focus on driving access to make an even more significant difference for patients. I would like to take this opportunity to thank my amazing friends and colleagues at Novartis. I have so many relationships that I have built over my years at Novartis, and memories to last a lifetime! I wish you and Novartis well in your transformative growth journey. Read more in our press release: https://lnkd.in/eWw3CCdN. #NewSandoz #PioneeringAccess
Mary Kemhus reposted this
One week from today! At this time, Wed., June 21, we'll be kicking off our hybrid "Employer Forum on Pharmacy Benefits, Specialty Drugs & Biopharma: How PBMs Control Prices and What Employers Can Do About It!" Check out the amazing agenda and join us! https://ow.ly/yPwy50OO79K #employers #mbghevents #pharmacybenefits #healthbenefits
